Portion by a grant from Merck and is serving as a consultant for Merck, Janssen, Glaxo Smith-Kline,Journal of your American Heart AssociationCombination Therapy and Lipoprotein Particle NumberLe et alORIGINAL RESEARCHAstra Zeneca, and XZK corporation. Dr Jin is a PhD candidate within the System on Nutrition in Health Sciences in the Laney School of Graduate Studies, Emory University. Drs Tershakovec, Neff, and Tomassini are personnel of Merck Sharp Dohme Corp., a subsidiary of Merck Co., Inc., Whitehouse Station, NJ and hold stock/stock options in the firm.18. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in sufferers with kind two diabetes mellitus and low-density lipoprotein cholesterol 100 mg/dl. Am J Cardiol. 2006;98:1599?602. 19. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery illness in the Pravastatin Limitation of Atherosclerosis inside the Coronary Arteries (PLAC-I) trial.1363210-41-6 Formula Am J Cardiol. 2002;90:89?four. 20. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009;32:1087?1091. 21. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the Ideal and EPIC-Norfolk studies. J Am Coll Cardiol. 2008; 51:634?42. 22. Insull W Jr, Toth PP, Superko HR, Thakkar RB, Krause S, Jiang P, Parreno RA, Padley RJ. Mixture of niacin extended-release and simvastatin final results inside a significantly less atherogenic lipid profile than atorvastatin monotherapy. Vasc Wellness Risk Manag. 2010;6:1065?075. 23. Toth PP, Thakker KM, Jiang P, Padley RJ. Niacin extended-release/simvastatin mixture therapy produces larger favorable alterations in high-density lipoprotein particles than atorvastatin monotherapy. Vasc Overall health Risk Manag. 2012;8:39?four. 24. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with sort IIa or type IIb hyperlipidemia. J Am Coll Cardiol. 2008;51:1564?572. 25. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle evaluation by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847?70. 26. Bays H, Conard S, Leiter LA, Bird S, Jensen E, Hanson ME, Shah A, Tershakovec AM.5-Bromo-2-methylpyridin-4-ol Price Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Wellness Dis.PMID:24456950 2010;9:136. 27. Winkler K, Jacob S, Muller-Schewe T, Hoffmann MM, Konrad T. Ezetimibe alone and in mixture lowers the concentration of modest, dense low-density lipoproteins in type two diabetes mellitus. Atherosclerosis. 2012; 220:189?93. 28. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases little dense low-density lipoproteins in healthful males: a randomized trial. Eur Heart J. 2010; 31:1633?639. 29. Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The impact of simvastatin alone versus simvastatin plus ezetimibe around the concentration of modest dense low-density lipoprotein cholesterol in subjects with main hyperc.
